Breakingviews: Biotech blues

Robert Cyran and Richard Beales examine why the failure of tests for a single drug caused Alnylam Pharmaceuticals to lose half its $6 bln market capitalization overnight.

Source: top Video

Leave a Reply

Your email address will not be published. Required fields are marked *

What Are You Waiting For?

Try Our Next Alert And See For Yourself!